Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

Januzzi, J. L. et al. (2022) Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. Journal of Hematology and Oncology, 15(1), 1. (doi: 10.1186/s13045-021-01221-z) (PMID:34991679) (PMCID:PMC8734305)

Abstract

Background: The phase 2 PACE (Ponatinib Ph+ ALL and CML Evaluation) trial of ponatinib showed robust long-term benefit in relapsed Philadelphia chromosome-positive (Ph+) leukemia; arterial occlusive events (AOEs) occurred in ≥ 25% of patients based on investigator reporting. However, AOE rates vary depending on the definitions and reporting approach used. Methods: To better understand clinically relevant AOEs with ponatinib, an independent cardiovascular adjudication committee reviewed 5-year AOE data from the PACE trial according to a charter-defined process and standardized event definitions. Results: A total of 449 patients with chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) received ponatinib (median age 59 y; 47% female; 93% ≥ 2 prior tyrosine kinase inhibitors (TKIs); median follow-up, 37.3 months). The adjudicated AOE rate (17%) was lower than the non-adjudicated rate (i.e., rate before adjudication; 25%). The only adjudicated AOE in > 2% of patients was peripheral arterial occlusive disease (4%). Exposure-adjusted incidence of newly occurring adjudicated AOEs decreased over time. Patients with multiple baseline cardiovascular risk factors had higher adjudicated AOE rates than those without risk factors. Conclusions: This independent adjudication study identified lower AOE rates than previously reported, suggesting earlier overestimation that may inaccurately reflect AOE risk with ponatinib. This trial was registered under ClinicalTrials.gov identifier NCT01207440 on September 23, 2010 (https://clinicaltrials.gov/ct2/show/NCT01207440).

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Petrie, Professor Mark
• Authors: Januzzi, J. L., Garasic, J. M., Kasner, S. E., McDonald, V., Petrie, M. C., Seltzer, J., Mauro, M., Croce, K., Berman, E., Deininger, M., Hochhaus, A., Pinilla-Ibarz, J., Nicolini, F., Kim, D.-W., DeAngelo, D. J., Kantarjian, H., Xu, J., Hall, T., Srivastava, S., Naranjo, D., and Cortes, J.
• College/School: College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
• Journal Name: Journal of Hematology and Oncology
• Publisher: BioMed Central
• ISSN: 1756-8722
• ISSN (Online): 1756-8722
• Copyright Holders: Copyright © The Author(s) 2022
• First Published: First published in Journal of Hematology and Oncology 15(1):1
• Publisher Policy: Reproduced under a Creative Commons Licence